Matches in Wikidata for { <http://www.wikidata.org/entity/Q64660802> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q64660802 description "clinical trial" @default.
- Q64660802 description "ensayu clínicu" @default.
- Q64660802 description "klinisch onderzoek" @default.
- Q64660802 description "клінічне випробування" @default.
- Q64660802 name "Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea" @default.
- Q64660802 type Item @default.
- Q64660802 label "Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea" @default.
- Q64660802 prefLabel "Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea" @default.
- Q64660802 P1050 Q64660802-66DF6723-114D-4DF4-9B19-2CA9EF212B6C @default.
- Q64660802 P1132 Q64660802-1CFD3708-F7D3-4E08-94F4-079F5E426FE9 @default.
- Q64660802 P1476 Q64660802-CFC261A0-E4AD-494A-9C8C-DD9B9489FE81 @default.
- Q64660802 P17 Q64660802-13C243B6-CCD3-41C7-90C4-55F7832096A9 @default.
- Q64660802 P17 Q64660802-41AA1F38-8983-4416-BC23-2321ACB183EA @default.
- Q64660802 P17 Q64660802-5F46A2AF-23CC-4FF2-B9F7-F358FFBFF343 @default.
- Q64660802 P17 Q64660802-A6460AAD-1A62-4214-9B72-EBFA3DE889AC @default.
- Q64660802 P17 Q64660802-C336671B-2524-4696-994D-41F75DA29496 @default.
- Q64660802 P17 Q64660802-DEB0FBB1-87BF-4978-9E9D-6B29FC67CF62 @default.
- Q64660802 P2899 Q64660802-E48C7E98-BBFC-4668-9A4B-420A7E6C982E @default.
- Q64660802 P3098 Q64660802-E7565EC1-7F8B-407E-BD3C-F5DF3487102B @default.
- Q64660802 P31 Q64660802-F00A7246-F26C-4967-9F52-DEEC0CE9B96A @default.
- Q64660802 P4844 Q64660802-9A555023-C59D-4167-8E73-4B131CCB3A53 @default.
- Q64660802 P580 Q64660802-71DD7CAE-CEA4-4AFB-B975-14A7C7692ED6 @default.
- Q64660802 P582 Q64660802-EDF110F4-079D-47DD-9D12-A0807BAA87D4 @default.
- Q64660802 P6099 Q64660802-43961773-1E2B-4DC1-BCB8-CAAF0C4AC40C @default.
- Q64660802 P767 Q64660802-17F4417E-9EB9-4B01-BA21-5C10FA08EAA7 @default.
- Q64660802 P8363 Q64660802-D44D4752-7C8D-4FB2-8F88-2327B0049A74 @default.
- Q64660802 P1050 Q12206 @default.
- Q64660802 P1132 "+311" @default.
- Q64660802 P1476 "A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea" @default.
- Q64660802 P17 Q16 @default.
- Q64660802 P17 Q183 @default.
- Q64660802 P17 Q213 @default.
- Q64660802 P17 Q214 @default.
- Q64660802 P17 Q29 @default.
- Q64660802 P17 Q36 @default.
- Q64660802 P2899 "+18" @default.
- Q64660802 P3098 "NCT01392677" @default.
- Q64660802 P31 Q30612 @default.
- Q64660802 P4844 Q19484 @default.
- Q64660802 P580 "2011-10-01T00:00:00Z" @default.
- Q64660802 P582 "2013-01-01T00:00:00Z" @default.
- Q64660802 P6099 Q42824827 @default.
- Q64660802 P767 Q266423 @default.
- Q64660802 P8363 Q78089383 @default.